Woodline Partners LP Adc Therapeutics Sa Transaction History

Woodline Partners LP

  • $11 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.92 - $5.45 $275,333 - $781,546
143,403 New
143,403 $279,000
Q3 2022

Nov 14, 2022
BUY
$4.66 - $10.31 $63,963 - $141,515
13,726 Added 40.56%
47,567 $229,000
Q2 2022

Aug 15, 2022
BUY
$5.96 - $14.99 $201,692 - $507,276
33,841 New
33,841 $269,000

Others Institutions Holding ADCT

# of Institutions
80
Shares Held
55.1M
Call Options Held
82.7K
Put Options Held
31.5K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $172M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email